Cargando…

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis

BACKGROUND: Pimavanserin, a selective 5-HT(2A) inverse agonist/antagonist, is the only treatment approved by the US Food and Drug Administration for hallucinations and delusions associated with Parkinson's disease (PD) psychosis. AIM: We aimed to evaluate motor- and cognition-related safety in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abler, Victor, Brain, Cecilia, Ballard, Clive, Berrio, Ana, Coate, Bruce, Espay, Alberto J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580496/ https://www.ncbi.nlm.nih.gov/pubmed/36277907 http://dx.doi.org/10.3389/fneur.2022.919778

Ejemplares similares

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications
por: Espay, Alberto J., et al.
Publicado: (2018)

Pimavanserin in Parkinson’s Disease-induced Psychosis: A Literature Review
por: Patel, Rikinkumar S, et al.
Publicado: (2019)

An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression
por: DeKarske, Daryl, et al.
Publicado: (2020)

Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis
por: Isaacson, Stuart H., et al.
Publicado: (2020)

Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
por: Rissardo, Jamir Pitton, et al.
Publicado: (2022)

Pimavanserin: Potential Treatment For Dementia-Related Psychosis
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
por: Combs, Brianna L, et al.
Publicado: (2017)

Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
por: Tampi, Rajesh R, et al.
Publicado: (2019)

Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice
por: Dashtipour, Khashayar, et al.
Publicado: (2021)

On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
por: Hacksell, Uli, et al.
Publicado: (2014)

Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature
por: Touma, Katie T. B., et al.
Publicado: (2018)

Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis
por: Brown, Joshua D, et al.
Publicado: (2021)

Pimavanserin for Psychosis in Parkinson’s Disease-Related Disorders: A Retrospective Chart Review
por: Sellers, Jessie, et al.
Publicado: (2019)

Dementia-related psychosis and the potential role for pimavanserin
por: Cummings, Jeffery L., et al.
Publicado: (2022)

Pimavanserin: A Truly Effective Treatment for Parkinson’s Disease Psychosis? A Review of Interventions
por: Heim, Beatrice, et al.
Publicado: (2023)

Long-term outcomes with pimavanserin for psychosis in clinical practice
por: Akbar, Umer, et al.
Publicado: (2022)

Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review
por: Srinivasan, Shilpa, et al.
Publicado: (2020)

Pimavanserin Use in Lewy Body Dementia: A Case Report Demonstrating the Medication’s Efficacy
por: Baker, Michelle, et al.
Publicado: (2023)

Sensory feedback in Parkinson's disease patients with “on”-predominant freezing of gait
por: Espay, Alberto J., et al.
Publicado: (2013)

Falls and Fractures in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2021)

Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2022)

HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis
por: Tariot, Pierre, et al.
Publicado: (2020)

Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series
por: Rothenberg, Kasia Gustaw, et al.
Publicado: (2023)

Repurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy
por: Ramachandran, Sharavan, et al.
Publicado: (2020)

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin
por: Caraci, Filippo, et al.
Publicado: (2020)

Erratum to: HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis
por: Tariot, Pierre, et al.
Publicado: (2021)

Editorial: Integrated Motor-Cognitive Aerobic Rehabilitation Approaches in Parkinson's Disease
por: Canesi, Margherita, et al.
Publicado: (2021)

Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study
por: Stubendorff, Kajsa, et al.
Publicado: (2014)

Assessment of Cognitive and Motor Skills in Parkinson's Disease by a Robotic Object Hitting Game
por: Wiratman, Winnugroho, et al.
Publicado: (2019)

Pimavanserin: A Novel Antipsychotic With Potentials to Address an Unmet Need of Older Adults With Dementia-Related Psychosis
por: Yunusa, Ismaeel, et al.
Publicado: (2020)

Skin Cancer May Delay Onset but Not Progression of Parkinson's Disease: A Nested Case-Control Study
por: Mahajan, Abhimanyu, et al.
Publicado: (2020)

Rationale and Design of the PAIRED Trial: Partnered Dance Aerobic Exercise as a Neuroprotective, Motor, and Cognitive Intervention in Parkinson's Disease
por: Hackney, Madeleine E., et al.
Publicado: (2020)

Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations
por: Fernandes, Mariana, et al.
Publicado: (2021)

Editorial: Biomarkers of non-motor symptoms in Parkinson's disease and parkinsonisms
por: Filippi, Massimo, et al.
Publicado: (2023)

Oculomotor Performances Are Associated With Motor and Non-motor Symptoms in Parkinson's Disease
por: Zhang, Yu, et al.
Publicado: (2018)

The Trajectory of Motor Deterioration to Death in Parkinson's Disease
por: Poonja, Sabrina, et al.
Publicado: (2021)

Knowledge, Responsibilities, and Peer Advice From Care Partners of Patients With Parkinson Disease Psychosis
por: Mantri, Sneha, et al.
Publicado: (2021)

Pisa Syndrome in Parkinson's Disease Is Associated With Specific Cognitive Alterations
por: Artusi, Carlo Alberto, et al.
Publicado: (2019)

Clinical Efficacy and Dosing of Vibrotactile Coordinated Reset Stimulation in Motor and Non-motor Symptoms of Parkinson's Disease: A Study Protocol
por: Pfeifer, Kristina J., et al.
Publicado: (2021)

Frequency and Dynamics of Non-motor Symptoms Presentation in Hispanic Patients With Parkinson Disease
por: Sánchez-Martínez, Claudia Marisol, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kqrsdlf2r2plm7hap7g53c6cme